• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Zentalis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    4/28/25 6:02:15 AM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZNTL alert in real time by email
    zntl-20250427
    0001725160FALSE00017251602025-04-272025-04-27


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ——————————————

    FORM 8-K
    ——————————————

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of report (Date of earliest event reported): April 27, 2025

    ——————————————  
    ZENTALIS PHARMACEUTICALS, INC.
    (Exact name of registrant as specified in its charter)   
    ——————————————
    Delaware 001-39263 82-3607803
    (State or other jurisdiction
    of incorporation or organization)
     
    (Commission
    File Number)
     
    (I.R.S. Employer
    Identification No.)
    10275 Science Center Drive, Suite 200
    San Diego, California 92121
    (Address of principal executive offices) (Zip Code)
    (858) 263-4333
    (Registrant’s telephone number, include area code)
    N/A
    (Former name or former address, if changed since last report)  
    ——————————————
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
     
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
     
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 




    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 par value per shareZNTLThe Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     




    Item 7.01 Regulation FD Disclosure.

    The posters furnished as Exhibits 99.1-99.4 to this Current Report on Form 8-K, and incorporated herein by reference, are being presented at the 2025 American Association for Cancer Research ("AACR") Annual Meeting, taking place April 25-30, 2025, in Chicago, IL.

    The information contained in Item 7.01 of this Current Report (including Exhibits 99.1-99.4 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.
    Item 9.01 Financial Statements and Exhibits.
    (d) Exhibits
    The following Exhibits 99.1-99.4 relating to Item 7.01 shall be deemed to be furnished, and not filed:
    Exhibit No.
     Description
    99.1 
    AACR poster titled "Loss of RB1 sensitizes TP53-mutated cancer cells to WEE1 inhibition by azenosertib"
    99.2
    AACR poster titled "Cell-free DNA molecular response predicts clinical efficacy in HGSOC patients treated with azenosertib"
    99.3
    AACR poster titled "Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumors"
    99.4
    AACR poster titled "The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor activity with encorafenib + cetuximab in multiple BRAFV600E models"
    104Cover Page Interactive Data File (embedded within the inline XBRL document)




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     ZENTALIS PHARMACEUTICALS, INC.
    Date: April 28, 2025 By: /s/ Julie Eastland
      Julie Eastland
      President and Chief Executive Officer

    Get the next $ZNTL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZNTL

    DatePrice TargetRatingAnalyst
    8/12/2024$4.00Underperform → Neutral
    Wedbush
    6/20/2024$28.00 → $5.00Buy → Neutral
    UBS
    6/18/2024$42.00 → $6.00Buy → Hold
    Jefferies
    6/18/2024$38.00 → $8.00Overweight → Equal-Weight
    Morgan Stanley
    6/18/2024$15.00 → $4.00Neutral → Underperform
    Wedbush
    6/18/2024Overweight → Equal Weight
    Wells Fargo
    11/8/2023$38.00 → $12.00Outperform → Neutral
    Wedbush
    11/7/2023$15.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $ZNTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.

      SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)

      11/14/24 4:20:13 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.

      SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)

      11/12/24 6:00:27 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.

      SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)

      11/6/24 2:47:51 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

      Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and othe

      3/26/25 4:05:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

      Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction of approximately 40% of employees Corporate event to be held on January 29, 2025 at 8:00am ET to provide key updates on azenosertib clinical data, development and regulatory path SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a restructuring of its business operations and research and development organ

      1/28/25 4:05:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Announces Key Management Appointments

      SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer. "Zentalis is sharply focused on our goal of bringing azenosertib to patients with gynecological malignancies," said Julie Eastland, Chief Executive Officer. "To support this goal, we are continuing to tune our leadership team and today announced the appointment of two talented leaders with a strong track record o

      12/12/24 7:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Financials

    Live finance-specific insights

    See more

    $ZNTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ZNTL
    SEC Filings

    See more

    $ZNTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ZNTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

      Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy cohorts in key clinical studies, well-characterized safety and tolerability profile shows no new safety signals Company aligned with FDA on seamless study design for DENALI Part 2 in patients with Cyclin E1+ PROC; study expected to begin 1H 2025 Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Management to host conference call today at 8:00 am ET SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (

      1/29/25 7:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

      FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the

      6/18/24 7:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

       ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D more than doubles exposure levels, maintains safety and improves tolerability with no treatment-related discontinuations Company plans to update efficacy data from Phase 1 monotherapy dose optimization study and provide program timeline updates for three azenosertib Phase 2 monotherapy trials currently enrolling patients at the RP2D in the second half of 2023 Investor call at 8:00 a.m. ET today to review azenosertib monotherapy data supporting dose selection and chemotherapy combination da

      6/6/23 6:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

      First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, announced financial results for the first quarter 2025 and highlighted recent oper

      5/14/25 4:05:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on May 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company's common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual's entering

      5/1/25 5:00:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

      Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). As previously d

      4/28/25 8:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)

      5/20/25 6:01:40 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Zentalis Pharmaceuticals Inc.

      S-8 - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)

      5/14/25 4:15:53 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Zentalis Pharmaceuticals Inc.

      10-Q - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)

      5/14/25 4:13:06 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharma upgraded by Wedbush with a new price target

      Wedbush upgraded Zentalis Pharma from Underperform to Neutral and set a new price target of $4.00

      8/12/24 8:08:44 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharma downgraded by UBS with a new price target

      UBS downgraded Zentalis Pharma from Buy to Neutral and set a new price target of $5.00 from $28.00 previously

      6/20/24 7:40:40 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharma downgraded by Jefferies with a new price target

      Jefferies downgraded Zentalis Pharma from Buy to Hold and set a new price target of $6.00 from $42.00 previously

      6/18/24 2:21:55 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Myers Scott Dunseth bought $29,373 worth of shares (21,000 units at $1.40), increasing direct ownership by 8% to 281,192 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      4/30/25 5:07:20 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Bruns Ingmar bought $45,656 worth of shares (20,000 units at $2.28), increasing direct ownership by 120% to 36,629 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      2/12/25 5:00:31 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PAO and Interim PFO Vultaggio Vincent was granted 158,586 shares and sold $4,476 worth of shares (2,615 units at $1.71), increasing direct ownership by 461% to 189,826 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      2/5/25 6:33:02 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Myers Scott Dunseth bought $29,373 worth of shares (21,000 units at $1.40), increasing direct ownership by 8% to 281,192 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      4/30/25 5:07:20 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Bruns Ingmar bought $45,656 worth of shares (20,000 units at $2.28), increasing direct ownership by 120% to 36,629 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      2/12/25 5:00:31 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Skvarka Jan bought $103,446 worth of shares (60,000 units at $1.72), increasing direct ownership by 67% to 149,551 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      2/4/25 4:45:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care